Related Experiment Video
Updated: Aug 12, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Rule set reduction using augmented decision table and semantic subsumption techniques: application to cholesterol
1Decision Systems Group, Harvard Medical School, Brigham and Women's Hospital, Boston, MA.
Abstract:
Clinical practice guidelines must comprehensively address all logically possible situations, but this completeness may result in sizable and cumbersome rule sets. We applied rule set reduction techniques to a 576-rule set regarding recommendations for medication treatment of hypercholesterolemia. Using decision tables augmented with information regarding test costs and rule application frequencies, we sorted the rule sets prior to identifying irrelevant tests and eliminating unnecessary rules. Alternatively, we examined the semantic relationships among risk factors in hypercholesterolemia and applied a subsumption technique to reduce the rule set. Both methodologies resulted in substantial rule set compression (mean, 48-70%). Subsumption techniques proved superior for compacting a large rule set based on risk factors.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
08:43A Study on an Intelligent Diagnosis and Treatment Assistant System for Acupuncture in Diminished Ovarian Reserve Based on a Knowledge Graph
Published on: May 29, 2026
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Phase I Reactions: Reductive Reactions
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management